How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Predictive Presymptomatic Testing Market
- By Test Type: Genetic Mutation Analysis, Biomarker Profiling, Whole Genome Sequencing, Epigenetic Testing, Proteomic Testing
- By Application: Alzheimer's Disease Risk Assessment, Cancer Predisposition Testing, Cardiovascular Disease Risk Prediction, Inherited Genetic Disorder Screening, Neurodegenerative Disease Prediction
- By End User: Hospitals and Clinics, Diagnostic Laboratories, Research Institutes, Direct-to-Consumer Testing Providers, Pharmaceutical and Biotechnology Companies
- By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray Analysis, Mass Spectrometry, Bioinformatics Platforms
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Genetic Mutation Analysis leads By Test Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Predictive Presymptomatic Testing Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Test Type 5
Application 5
End User 5
Technology 5
Companies profiled
Myriad Genetics Inc.
Invitae Corporation
GeneDx (a subsidiary of BioReference Laboratories)
Ambry Genetics Corporation
Fulgent Genetics Inc.
Natera Inc.
Color Genomics Inc.
Counsyl (now part of Myriad Genetics)
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings (LabCorp)
Mayo Clinic Laboratories
Sema4
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Myriad Genetics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Invitae Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →GeneDx (a subsidiary of BioReference Laboratories)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ambry Genetics Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Fulgent Genetics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Natera Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Color Genomics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Counsyl (now part of Myriad Genetics)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Quest Diagnostics Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Laboratory Corporation of America Holdings (LabCorp)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mayo Clinic Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sema4
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →PathAI
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Guardant Health Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →23andMe
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,792M by 2033 · 5.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Genetic Mutation Analysis38.3
- Biomarker Profiling12.6
- Whole Genome Sequencing19.3
- Epigenetic Testing11.6
- Proteomic Testing18.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,461M → $2,228M · 5.4%
Europe$1,019M → $1,707M · 6.7%
Asia Pacific$930.0M → $1,574M · 6.8%
Latin America$575.7M → $874.3M · 5.4%
Middle East and Africa$442.9M → $746.0M · 6.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.442026
5.462027
5.482028
5.472029
5.502030
5.512031
5.522032
5.522033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Myriad Genetics Inc.24.8
- Invitae Corporation15.0
- GeneDx (a subsidiary of BioReference Laboratories)10.4
- Ambry Genetics Corporation4.4
- Fulgent Genetics Inc.10.9
- Natera Inc.6.4
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Test Type29.1%
Application13.4%
End User27.1%
Technology30.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.2
- Europe23.9
- Asia Pacific22.1
- Latin America12.3
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Myriad Genetics Inc. | 95 | 77 | 83 | 76 | 85 | 91 | 85 |
| Invitae Corporation | 75 | 76 | 86 | 90 | 68 | 69 | 77 |
| GeneDx (a subsidiary of BioReference Laboratories) | 75 | 78 | 86 | 70 | 83 | 88 | 80 |
| Ambry Genetics Corporation | 75 | 76 | 69 | 78 | 63 | 67 | 71 |
| Fulgent Genetics Inc. | 58 | 72 | 72 | 57 | 62 | 54 | 63 |
| Natera Inc. | 57 | 66 | 52 | 46 | 51 | 60 | 55 |
| Color Genomics Inc. | 43 | 43 | 45 | 42 | 50 | 44 | 45 |
| Counsyl (now part of Myriad Genetics) | 52 | 52 | 41 | 46 | 38 | 40 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Myriad Genetics Inc.
- Invitae Corporation
- GeneDx (a subsidiary of BioReference Laboratories)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Myriad Genetics Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Invitae Corporation | ✓ | ◐ | ◐ | ✓ | ✓ | ✓ |
| GeneDx (a subsidiary of BioReference Laboratories) | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Ambry Genetics Corporation | ✓ | ◐ | ◐ | ✓ | ◐ | − |
| Fulgent Genetics Inc. | − | − | ◐ | ◐ | ◐ | − |
| Natera Inc. | − | ◐ | ◐ | − | ◐ | ◐ |
| Color Genomics Inc. | − | − | ◐ | − | ◐ | ◐ |
| Counsyl (now part of Myriad Genetics) | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Myriad Genetics Inc.85
2GeneDx (a subsidiary of BioReference Laboratories)80
3Invitae Corporation77
4Ambry Genetics Corporation71
5Fulgent Genetics Inc.63
6Natera Inc.55
7Color Genomics Inc.45
8Counsyl (now part of Myriad Genetics)45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Myriad Genetics Inc.GeneDx (a subsidiary of BioReference Laboratories)
Challenger2
Strong scale, closing on the leaders.
Invitae CorporationAmbry Genetics Corporation
Contender1
Focused players with pockets of strength.
Fulgent Genetics Inc.
Niche3
Specialists in a single segment or region.
Natera Inc.Color Genomics Inc.Counsyl (now part of Myriad Genetics)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Test Type in North America, then scale across Predictive Presymptomatic Testing Market — a $401M beachhead inside a $6.89B market.
Beachhead (SOM)$401Mobtainable near-term
Serviceable (SAM)$2.82Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Genetic Mutation Analysis
Best fit — highest urgency & budget in Test Type.
Economic buyer78 fit
Biomarker Profiling
Strong fit — clear ROI and a fast path to value.
End user67 fit
Whole Genome Sequencing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Test Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Test Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Predictive Presymptomatic Testing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified25%
Evaluation12%
Closed-won8%
$12.7KCAC
$50KLTV
3.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Predictive Presymptomatic Testing Market is a high-growth opportunity — $4.21B by 2033, compounding at 10.1%.
TAM · 2025$1.95Btoday
TAM · 2033$4.21Bforecast
CAGR10.1%2027–2033
Cumulative$26.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.21BTotal addressable market
SAM$1.66BServiceable available market
SOM$342MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.1% CAGR
Demand compounds through 2033, outpacing GDP across Test Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Test Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.21BLarge & growingTAM by 2033 at 10.1% CAGR
$1.66BServiceable nowreachable with today’s model
$342MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.28BBear6.6% CAGR
$4.21BBase10.1% CAGR
$5.39BBull13.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Predictive Presymptomatic Testing Market — a $4.52B market by 2033. Plan: grow share from 7.5% to 16.5%.
Market size · 2033$4.52Btotal addressable
Market CAGR9.2%2027–2033
Target share16.5%from 7.5% today
Revenue ambition$745Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.5% | 16.5% | Behind |
| Revenue | $363M | $745M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 36.6% | 39.9% | On track |
| Customer retention | 85.3% | 93.6% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Test Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Test Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $87M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Test Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Predictive Presymptomatic Testing Market conversation — a $754M market you can size, segment and defend in minutes.
Market size · 2033$754Mtotal opportunity
Growth3.9%CAGR to 2033
Addressable buyers925+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Test Type
Goal Grow share in Test Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 4 mopayback period
$86K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Myriad Genetics Inc.Invitae CorporationGeneDx (a subsidiary of BioReference Laboratories)Ambry Genetics CorporationFulgent Genetics Inc.Natera Inc.Color Genomics Inc.Counsyl (now part of Myriad Genetics)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Predictive Presymptomatic Testing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Predictive Presymptomatic Testing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Predictive Genetic Testing and Genomics Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportPredictive Genetic Testing And Consumer Genomics Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportPredictive Genetic Counseling Service Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportPredictive and Presymptomatic Testing Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportPrecut Splints Market
Market size, share, segmentation and regional forecast.
$418M market · 2025 base year
View reportPrecordial Stethoscope Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportPreclinical X-ray Imaging Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportPreclinical Ultrasound System Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportPreclinical Tomography System for Biopharmaceuticals Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportPre-Clinical Testing Service Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportPreclinical Small Animal Imaging System Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportPreclinical Single Photon Emission Computed Tomography (SPECT) Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.